Mizuho raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $20 from $13 and keeps an Outperform rating on the shares. The company reported positive Phase 1 data for soquelitinib in atopic dermatitis, the analyst tells investors in a research note. The new the new data were “outstanding” and support a view of soquelitinib being a potential best-in-disease agent in atopic dermatitis, contends Mizuho. Corvus remains a top Mizuho pick for January.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVS:
- Midday Fly By: Netflix and Warner amend deal, GSK to acquire Rapt
- Corvus Pharmaceuticals: Undervalued Buy on Soquelitinib’s Promising Data, Expanding Immunology Pipeline, and Multiple Upcoming Catalysts
- Corvus Pharmaceuticals price target raised to $27 from $11 at H.C. Wainwright
- Corvus Pharmaceuticals reports positive Phase 1 soquelitinib results
- Corvus announces results from cohort 4 of Phase 1 trial of soquelitinib